Seattle Genetics wins priority review for Hodgkin's/ALCL drug, but US FDA splits app
This article was originally published in Scrip
Executive Summary
Seattle Genetics reported that the US FDA has accepted for filing its biologics license applications (BLAs) for brentuximab vedotin as a treatment for patients with relapsed or refractory Hodgkin's lymphoma and as a therapy for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) – with both applications gaining six-month priority review status.